Application of belinostat in preparation of medicine for preventing, relieving and/or treating multiple sclerosis

A multiple sclerosis, belistat technology, used in the field of medicine

Active Publication Date: 2021-06-18
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the direct or indirect therapeutic effect of belinostat in multiple sclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of belinostat in preparation of medicine for preventing, relieving and/or treating multiple sclerosis
  • Application of belinostat in preparation of medicine for preventing, relieving and/or treating multiple sclerosis
  • Application of belinostat in preparation of medicine for preventing, relieving and/or treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: The effect of belistat on the behavior of mice with experimental autoimmune encephalomyelitis

[0036] 1.1 Establishment and administration of experimental autoimmune encephalomyelitis mouse model

[0037] Experimental principle

[0038] MOG for C57BL / 6 mice 35-55 Induce experimental autoimmune encephalomyelitis (experimentallyallergic encephalomyelitis, EAE) model.

[0039] experimental method

[0040] Female C57BL / 6 mice, 6-8 weeks old, weighing 18-20g, were subcutaneously injected with MOG after 1 week of adaptive feeding 35- 55 300μg and 600ng of pertussis toxin were injected intraperitoneally to establish the EAE model. A normal control group was set, n=10. After 11 days of modeling, the animals began to develop symptoms, with varying degrees of limb paralysis. Mice with limb paralysis were selected as the experimental autoimmune encephalomyelitis model.

[0041] On the 13th day of modeling, the female C57BL / 6 mice were randomly divided into two ...

Embodiment 2

[0083] Example 2: Effects of Belinostat on Inflammatory Cell Infiltration, Demyelination and Microglial Cell Proliferation in the Spinal Cord of EAE Model Mice

[0084] 2.1 Establishment and administration of EAE mouse model

[0085] Experimental principles, experimental methods, and experimental results are the same as in Example 1.1.

[0086] 2.2 Effect of belistat on the infiltration of inflammatory cells in the spinal cord of EAE mice

[0087] experimental method

[0088] On the 28th day after modeling, 3 mice in each group were anesthetized with 4% chloral hydrate. Perfuse with normal saline first, wait until the color of the liver turns white, and then perfuse with 4% paraformaldehyde until the limbs of the animal become stiff. The head was decapitated, and the lumbar enlarged part of the spinal cord was fixed in 4% paraformaldehyde. Paraffin sections were made from the lumbar spinal cord and stained with hematoxylin-eosin (H&E) to observe the infiltration of inflammat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of belinostat in preparation of a medicine for preventing, relieving and/or treating multiple sclerosis. In a mouse experimental autoimmune encephalomyelitis model, belinostat shows a good treatment effect, and can effectively treat pathological changes and progression of diseases. The therapeutic effect is achieved by inhibiting proliferation of microglial cells in a central nervous system.

Description

technical field [0001] The invention relates to the application of belistat in the preparation of drugs for preventing, alleviating and / or treating multiple sclerosis, and belongs to the technical field of medicine. Background technique [0002] Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory demyelinating lesions of the central nervous system, which has the characteristics of high recurrence and disability. Clinical manifestations include paralysis, numbness, cramps, aphasia, and visual impairment. Epidemiological studies have shown that 50-300 people in every 100,000 people suffer from multiple sclerosis, and there are 2.3 million people in the world suffering from multiple sclerosis, mainly concentrated in European and American countries. The prevalence of multiple sclerosis increases with latitude, and the incidence of multiple sclerosis in women is twice that of men (Neurology.2014; 83(11):1022-1024). The etiology of multiple sclerosis i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/18A61K45/06A61P25/28A61P37/02
CPCA61K31/18A61K45/06A61P25/28A61P37/02Y02A50/30
Inventor 杜冠华李莉申艳佳刘德培陈厚早杨海光杨冉
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap